Your partners in growth and success
KPATH Scientific, LLC
We are passionate about building solutions and products that solve important problems, and building teams who are equally passionate about achieving those goals. We launched KPATH Scientific, LLC to let us transfer what we have learned in industry and research to the companies who can benefit most from experienced guidance.
We bring diverse engineering, scientific, product and managerial experience and domain expertise to bear on problems facing many high-tech startups and growing companies.
The name KPATH comes from a system LLNL built after the 9/11 attacks to fully automate the design of PCR signatures to detect any microbial organism for which a full genome was available. While it may appear to mean "thousands of pathogens", it actually was meant to resemble the call sign of a radio station ("You're listening to KPATH: The pathogen hits of yesterday and today; all pathogens, all the time!") Establishment of the KPATH system in 2003 just in time to aid the CDC to create an assay for the SARS outbreak helped brand the LLNL pathogen bioinformatics team as a leader in applying advance genomic analyses in the service of biodefense and public health.
Co-founder and CEO
A computer scientist by training, Tom is a recognized expert in pathogen detection and bioinformatics. He has served on 5 National Academy of Science committees and regularly is called upon by the CDC and FDA to consult. This included co-chairing the 2011 Blue Ribbon Panel on bioinformatics for the CDC that directly led to Congressional funding for the Advanced Molecular Detection program, and twice chairing the NIAID proposal review committees that evaluated proposals for major 5-year Genome Sequencing and Infectious Disease centers contracts. In May 2020 Tom was one of 4 people the CDC asked to review their new COVID-19 + Influenza A/B multiplex assay prior to submission to the FDA for Emergency Use Authorization. EUA was granted in early July and this assay will be in use by public health labs nationwide in time for the coming Flu season.
For over 30 years Tom has also done independent bioinformatics consulting and management coaching. Clients have included pharmaceutical, sequencing, PCR, CRISPR gene editing, and microbiome companies, plus research institutions, hospitals and government agencies. Engagements have ranged from single-day to multi-year and have included bioinformatics information system design, recruiting and hiring assistance, and coaching beginning and experienced managers. Tom is currently on the board of directors for LexaGene, a point-of-care PCR startup in Boston; he consults for Inscripta, a CRISPR startup in Boulder; and he is an advisor for several nascent biotech startups.
Prior to starting his own consulting firm in 2018, Tom spent decades of applying computer science and team building/managing in support of leading-edge biological research at Lawrence Livermore National Laboratory (LLNL). This includes 14 years building bioinformatics systems to support the physical mapping and sequencing of human chromosome 19 as part of the Human Genome Project. Tom was also part of the team that built and continues to support the nationwide BioWatch system since 2003. The LLNL bioinformatics team Tom led has been focused on improving ways of detecting and characterizing dangerous pathogens since they first started building a wide-area biodetection system for use at the 2002 Winter Olympics. Tom has secured and managed over $75M in bioinformatics contracts since 2000 from DHS, DoD, DOE, and other federal agencies.
Tom's LLNL bioinformatics team pioneered the use of fully-automated computational genomic analyses to design the DNA signatures for PCR assays. Since 2000 the LLNL team worked with researchers at the CDC to improve detection signatures for many pathogens, including the causative agents of anthrax, plague, tularemia, SARS, monkeypox and smallpox. In 2003 they responded to an outbreak of Newcastle disease virus in poultry in California, developing a new PCR diagnostic to speed the diagnosis time from 6-12 days down to 4 hours. They subsequently automated the design of multiplex PCR signatures and built the first microarray to detect all sequenced bacteria and viruses at the whole-genome level. In recent years, the latest versions of this array can process 24 or 96 samples in parallel, each sample being exposed to 1.4 million DNA probes that have been designed computationally to detect over 12,000 unique species of bacteria, viruses, fungi, archaea, and protozoa. The LLNL team has also developed DNA sequence analysis software for complex clinical or environmental samples (LMAT, the Livermore Metagenomics Analysis Toolkit) and targeted sequencing panels for improving the detection of biothreat agents and antimicrobial resistance.
Co-founder and COO
Yan is a passionate market-driven and strategic software technology and product leader with a wealth of experience and a successful track record developing, managing, and delivering innovative solutions to market. The combination of hands-on software development and management expertise with business acumen allowed her to effectively develop, market, and enable sales and product growth throughout her career; partnering with teams and ecosystems, and working with global companies and customers, from multi-million dollar programs to hundreds of millions dollars/year products.
She has proven success in building and leading development teams and creating and managing product strategy, positioning, roadmap, requirements, priorities, pricing, licensing, globalization, and launch with in-depth market and competitive research and analysis. With demonstrated expertise in marketing messaging, go-to-market strategy, content creation, sales enablement, field and customer training, and analyst whitepapers and reports, she has also been a speaker at many international conferences and industry events to educate and promote market leading products and solutions.
Before founding KPATH Scientific, LLC Yan was the senior product and marketing manager for Coverity product, a market leading static analysis tool for software quality and security testing, at Synopsys Software Integrity Group. Prior to Synopsys, Yan was the director of software engineering at Cryptography Research and senior director of software development at CPU Technology where she led development teams creating products and solutions in cybersecurity, embedded system, medical instrumentation, commercial and consumer electronic industries. She has in-depth knowledge and hands-on experience in software development lifecycle, building safe and secure software, leading technology development team, and creating market-driven innovative products and solutions. Yan has a bachelor degree in Biomedical Engineering, a master degree in Electrical and Electronic Engineering, and an MBA.
Giving back experience and knowledge to the industries and causes she cares about the most, Yan is excited to provide consulting and services in the areas of product management, marketing, development, and security with effective frameworks, methodologies, processes, tools, and practices.